Finnish nanotechnology company Nanoform has announced construction of a new 600m2 GMP manufacturing facility at Viikki Life Science Park in Helsinki. The plant, which is expected to be operational sometime in 2019, will result in a six-fold increase the company’s capacity for nanonization of API for clinical trial use and will add the capability to handle potent APIs. Funding for the expansion was partially provided by a €7 million private placement.
According to the company, its supercritical CO2 technology is capable of producing particles from 10 nm to 2 µm and can control the polymorphism of the particles. The company cites an increased ability for these particles to cross the blood brain barrier when delivered intranasally as a potential benefit of the process.
Nanoform Chief Commercial Officer Christian Jones commented, “We are very excited to announce the constructionof our new GMP-compliant facility, a key milestone in our growth strategy. We believe we are the only company globally that can produce excipient-free nanoparticles below 200nm directly from solution and at scale, whilst controlling their physico-chemical attributes. This offers significant advantage for our customers development molecules, enabling solutions to problematic compounds, transforming existing formulations and adding lifecycle protection to current pipeline drugs.”
Read the Nanoform press release.
